Nakafri (Fluticasone Propionate)

Fluticasone propionate in Nakafri binds to glucocorticoid receptors in nasal mucosal cells, altering gene expression to suppress inflammatory mediators. This reduces swelling, mucus production, and immune cell activity, providing localized anti‑inflammatory effects.

The prescribed dose of Nakafri is determined by the treating clinician based on the patient’s age, severity of symptoms, and response to therapy. Patients should follow the specific instructions provided by their healthcare professional.

Safety data for Nakafri in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against possible risks and consider alternative therapies if appropriate. Women should discuss use with their obstetrician or physician.

To request Nakafri, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nakafri contains fluticasone propionate, a potent glucocorticoid with high local activity and low systemic absorption, similar to other intranasal steroids such as mometasone or budesonide. Choice among them often depends on formulation preferences, dosing frequency, and individual patient response.

Nakafri should be stored at room temperature, below 25 °C, in its original packaging. Keep the spray bottle tightly closed, protect it from moisture and direct sunlight, and avoid freezing.

Nakafri is a nasal spray applied directly into each nostril. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle, and spray the prescribed number of actuations while breathing in gently. Detailed instructions are provided with the product.

Serious but rare risks include adrenal suppression, cataracts or glaucoma, severe allergic reactions such as anaphylaxis, fungal infections of the nasal mucosa, and perforation of the nasal septum. Patients should report any unusual symptoms to their healthcare provider promptly.

Nakafri is contraindicated in individuals with known hypersensitivity to fluticasone propionate or any component of the formulation. It should also be avoided in patients with active untreated nasal infections or those already using another intranasal corticosteroid without medical supervision.